Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saadia, D.
Right arrow Articles by Kaufmann, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saadia, D.
Right arrow Articles by Kaufmann, H.
Related Collections
Right arrow Autonomic diseases
Right arrow Botulinum toxin
Neurology 2001;57:2095-2099
© 2001 American Academy of Neurology


Articles

Botulinum toxin type A in primary palmar hyperhidrosis

Randomized, single-blind, two-dose study

Daniela Saadia, MD;, Andrei Voustianiouk, PhD;, Annabel K. Wang, MD and Horacio Kaufmann, MD

From the Department of Neurology, Mount Sinai School of Medicine, New York, NY.

Address correspondence and reprint requests to Dr. Horacio Kaufmann, Mount Sinai School of Medicine, Box 1052, New York, NY 10029; e-mail: Horacio.Kaufmann{at}mssm.edu

Background:— Primary palmar hyperhidrosis is characterized by excessive sweating due to increased sympathetic cholinergic sudomotor nerve traffic to the palmar surface of the hands. Clinical studies suggest that intradermal injections of botulinum toxin are effective in the treatment of palmar hyperhidrosis.

Objectives:— To establish the effectiveness of intradermal botulinum toxin in reducing hyperhidrosis, to determine the most effective dose of toxin, and to examine its effect on muscle strength.

Methods:— In a prospective, single blind, randomized trial, 24 patients with severe palmar hyperhidrosis received either a low (50 U) or a high dose (100 U) of botulinum toxin type A (Botox, Allergan) injected intradermally in 20 sites in each palm.

Results:— Following injection with either dose, iodine starch test revealed a significant decrease in sweating within the first month. Six months after injection, the anhidrotic effect was still evident in two thirds of the patients in both groups. Handgrip strength was not affected with either dose but finger pinch strength, 2 weeks after the injection, decreased 23 ± 27% with 50 U (p < 0.05) and 40 ± 21% with 100 U (p < 0.001). Pinch strength improved gradually but 6 months after treatment it was still 7–11% lower than at baseline.

Conclusions:— Both 50 and 100 U of botulinum toxin type A, injected intradermally in each hand, decreased sweating in patients with primary hyperhidrosis for at least 2 months in all the patients, and 6 months in most patients. Weakness in the intrinsic muscles of the hand was observed.




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
V. Ambrogi, E. Campione, D. Mineo, E. J. Paterno, E. Pompeo, and T. C. Mineo
Bilateral thoracoscopic t2 to t3 sympathectomy versus botulinum injection in palmar hyperhidrosis.
Ann. Thorac. Surg., July 1, 2009; 88(1): 238 - 245.
[Abstract] [Full Text] [PDF]


Home page
Hand TherHome page
J. Keir and H. P Giele
Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Hand Ther, June 1, 2009; 14(2): 32 - 38.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. Naumann, Y. So, C. E. Argoff, M. K. Childers, D. D. Dykstra, G. S. Gronseth, B. Jabbari, H. C. Kaufmann, B. Schurch, S. D. Silberstein, et al.
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, May 6, 2008; 70(19): 1707 - 1714.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Podiatr. Med. Assoc.Home page
T. C. Vlahovic, S. P. Dunn, J. C. Blau, and C. Gauthier
Injectable Botulinum Toxin as a Treatment for Plantar Hyperhidrosis: A Case Study
J Am Podiatr Med Assoc, March 1, 2008; 98(2): 156 - 159.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
J. H. Eisenach, J. L. D. Atkinson, and R. D. Fealey
Hyperhidrosis: Evolving Therapies for a Well-Established Phenomenon
Mayo Clin. Proc., May 1, 2005; 80(5): 657 - 666.
[Abstract] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J Jankovic
Botulinum toxin in clinical practice
J. Neurol. Neurosurg. Psychiatry, July 1, 2004; 75(7): 951 - 957.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. H. Schick, K. Fronek, A. Held, F. Birklein, W. Hohenberger, and M. Schmelz
Differential effects of surgical sympathetic block on sudomotor and vasoconstrictor function
Neurology, June 10, 2003; 60(11): 1770 - 1776.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.